Intermittent explosive disorder (IED) is the DSM-5-TR diagnosis for recurrent, impulsive, grossly out-of-proportion aggressive outbursts that cause distress or psychosocial impairment and are not better explained by another disorder. It is common: roughly one in twenty US adults meets lifetime criteria, yet under-recognized, under-treated, and frequently dismissed as a "personality" or "anger management" problem rather than a psychiatric condition. Onset is typically in late childhood or early adolescence, the course is often chronic, and the disorder runs alongside high rates of mood, anxiety, and substance use comorbidity, with elevated rates of self-directed violence. The evidence base for treatment is thin compared with other DSM disorders: fluoxetine and cognitive behavioral therapy show the most consistent benefit in small randomized trials, but effect sizes are modest and remission rates well below 50%. The bottom line for the resident: ask about Anhedonia-free explosive anger directly, screen for it when you see comorbid mood or substance use, and do not let the diagnosis go un-named because the symptom looks behavioral.

IED is more common than most clinicians estimate, with strikingly high rates in adolescents and a strong male predominance.

Prevalence

• In the National Comorbidity Survey Replication (NCS-R), lifetime prevalence in US adults was 7.3% using broad DSM-IV criteria and 5.4% using narrow criteria; 12-month prevalence was 3.9% (broad) and 2.7% (narrow).¹
• In the adolescent supplement (NCS-A), lifetime DSM-IV IED reached 7.8% by age 17, with a mean onset of 12 years and persistence into adulthood in roughly 80% of cases.²
• Cross-national estimates from the World Mental Health (WMH) Surveys are lower and highly variable, from 0.1% to 2.7% lifetime, reflecting both true cross-cultural variation and methodological differences in case finding.³
• A WMH analysis using DSM-5 criteria reported a pooled cross-national lifetime prevalence of 0.8%, with most cases showing an externalizing pattern of comorbidity.⁴
• Even in conflict-exposed populations such as post-war Iraq, lifetime prevalence was 1.7%, comparable to many higher-income settings.⁵

Demographics and onset

• Onset clusters in late childhood and early adolescence, with a mean of 12-14 years across major surveys.^1-2
• Male-to-female ratio is approximately 2:1 in community samples, narrowing somewhat in clinical populations.^3,6
• IED is more common in younger adults and declines with age, consistent with a developmental course in which impulsive aggression attenuates over decades.¹

Comorbidity and burden

• Lifetime comorbidity is the rule rather than the exception, with elevated rates of major depressive disorder, anxiety disorders, substance use disorders, and other impulse-control disorders.^1-2
• In NCS-A adolescents, more than 60% with IED had at least one other lifetime DSM-IV disorder, and the disorder typically preceded onset of comorbid mood, anxiety, and substance disorders.²
• Despite high morbidity, treatment-seeking is rare: in NCS-R, only 28.8% of those with lifetime IED had ever received treatment specifically for anger.¹

IED sits at the intersection of impaired top-down prefrontal control and exaggerated limbic threat reactivity, with serotonergic dysregulation as the most consistently implicated neurotransmitter abnormality.⁶

Neurobiology

• Functional MRI studies show Amygdala hyperreactivity to angry faces and reduced orbitofrontal cortex activation in IED relative to healthy controls and psychiatric controls without aggression.⁷
• The amygdala-orbitofrontal functional coupling that normally constrains aggressive responding is attenuated, supporting a "failed top-down control" model of impulsive aggression.⁷
• Greater amygdala activation to explicit anger cues correlates with the number of past aggressive acts, linking the imaging signal to overt behavior.⁸
• Serotonergic measures (cerebrospinal fluid 5-HIAA, prolactin response to serotonergic challenge, and platelet serotonin transporter density) are reduced in subjects with impulsive aggression across multiple personality and impulse-control diagnoses.⁶

Genetics and family history

• Twin studies of self-reported aggression yield heritability estimates of approximately 28-47% for hostility and assault subscales, supporting a meaningful but partial genetic contribution.⁹
• First-degree relatives of probands with IED show elevated rates of IED and of impulsive-aggressive traits, independent of comorbid mood or substance use disorders.⁶
• Parental psychopathology, particularly parental mood and substance use disorders, is overrepresented in childhood histories of adults with IED.¹⁰

Environmental contributors

• Exposure to interpersonal violence, harsh parenting, and childhood maltreatment is consistently associated with adult IED and with greater outburst frequency and severity.^3,10
• A two-hit model, in which serotonergic vulnerability is amplified by adverse early environments, fits the available data better than either a purely biological or purely environmental account.⁶

DSM-5-TR places IED in the chapter on Disruptive, Impulse-Control, and Conduct Disorders, defining it as recurrent behavioral outbursts representing failure to control aggressive impulses.¹¹

Core DSM-5-TR criteria

• Recurrent behavioral outbursts representing a failure to control aggressive impulses, meeting either of two frequency thresholds:¹¹
  • Verbal aggression (tantrums, tirades, verbal arguments or fights) or physical aggression toward property, animals, or other individuals, occurring on average twice weekly for three months, with property damage or injury absent.¹¹
  • Three behavioral outbursts involving property damage and/or assault causing physical injury, occurring within a 12-month period.¹¹
• The magnitude of the aggression is grossly out of proportion to the provocation or any precipitating psychosocial stressor.¹¹
• The aggressive outbursts are not premeditated (impulsive or anger-based) and are not committed to achieve a tangible objective.¹¹
• The outbursts cause marked distress, occupational or interpersonal impairment, or are associated with financial or legal consequences.¹¹
• Chronological age of at least six years (or equivalent developmental level).¹¹
• The outbursts are not better explained by another mental disorder, medical condition, or the physiological effects of a substance.¹¹

Key clinical commentary

• The "twice-weekly verbal/non-destructive" pathway, new in DSM-5, captures the larger and clinically important group of frequent low-damage outbursts that DSM-IV missed by requiring destructive acts.⁶
• Outbursts are typically short in duration, often under 30 minutes, with rapid escalation and a sense of relief afterward followed by remorse.⁶
• The diagnosis can be made alongside ADHD, conduct disorder, oppositional defiant disorder, autism spectrum disorder, or a personality disorder when impulsive aggressive outbursts exceed what those conditions usually explain.¹¹
• The diagnosis is not made if the outbursts occur exclusively during a major depressive episode, a manic episode, a psychotic disorder, or another condition that better accounts for the aggression.¹¹

ICD-11 placement

• ICD-11 retains intermittent explosive disorder (6C73) within Impulse Control Disorders, with criteria broadly similar to DSM-5-TR though slightly less specific on frequency thresholds.¹²
• ICD-11 emphasizes the recurrent, impulsive, and disproportionate nature of outbursts and explicitly distinguishes IED from oppositional defiant disorder and conduct-dissocial disorder.¹²

The prototypical IED outburst is a brief, high-intensity rage episode triggered by a minor interpersonal provocation, followed by rapid de-escalation, dysphoria, and self-reproach.⁶

Symptom pattern

• Outbursts are stereotyped within the individual, with rapid onset (seconds to minutes), peak intensity within minutes, and total duration typically under 30 minutes.⁶
• Provocations are usually interpersonal and trivial in objective magnitude (being cut off in traffic, a perceived slight, a partner's tone), yet are appraised as intolerable in the moment.⁶
• Autonomic arousal is prominent during outbursts: tachycardia, diaphoresis, chest tightness, tremor, and a subjective "racing" or "explosion" sensation.⁶
• Post-outburst phenomenology includes fatigue, relief, embarrassment, guilt, and, in many patients, partial amnesia for the event.⁶

Course

• Onset typically occurs in late childhood or early adolescence, with a mean age of onset of 12-14 years across major surveys.^1-2
• The disorder is usually chronic, with waxing and waning frequency over decades; episodic remission is reported, but full sustained remission without treatment is uncommon.^2,6
• Outbursts tend to attenuate in frequency and severity from middle age onward, paralleling the broader developmental decline in impulsive aggression.¹

Functional impact

• IED is associated with substantial impairment in family, occupational, and legal domains, including domestic violence perpetration, motor vehicle aggression, workplace conflict, and arrest history.^1,6
• Self-directed aggression (suicidal ideation, suicide attempts, and non-suicidal self-injury) is markedly elevated, independent of comorbid mood disorder.^1,6

The diagnostic task in IED is less "is this disorder present" than "is the aggression better explained by something else." Most differentials hinge on whether outbursts are impulsive and disproportionate (favoring IED) versus premeditated, mood-state-bound, or accounted for by another condition.¹¹

Psychiatric differentials

• Bipolar disorder: irritability and aggression occur during manic, hypomanic, or mixed episodes and remit between episodes; IED is diagnosed only if outbursts persist outside mood episodes.¹¹
• Borderline personality disorder: anger is reactive to perceived abandonment and embedded in affective instability and identity disturbance; both diagnoses may co-occur if IED outbursts exceed what BPD usually explains.^6,11
• Antisocial personality disorder: aggression is often premeditated, goal-directed, and lacking remorse, in contrast to the impulsive remorseful pattern of IED.^6,11
• Conduct disorder and oppositional defiant disorder: in patients aged 6-18, DSM-5-TR allows IED to be diagnosed alongside these conditions only when impulsive aggressive outbursts exceed those typically seen in CD or ODD and warrant independent clinical attention.¹¹
• Attention-deficit/hyperactivity disorder: impulsivity is core but aggression is not required; IED is added when explosive outbursts dominate the picture and exceed what ADHD alone explains.¹¹
• Autism spectrum disorder: outbursts are often triggered by sensory overload or change in routine and are stereotyped to those triggers; IED requires outbursts disproportionate to provocation in a broader range of situations.¹¹
• Post-traumatic stress disorder: irritable and aggressive behavior is a Criterion E symptom of PTSD and is tied to trauma cues; IED outbursts occur independent of trauma-related cues.¹¹
• Disruptive mood dysregulation disorder: in children, persistent irritable mood between outbursts argues for DMDD rather than IED, which features near-baseline mood between outbursts.¹¹
• Substance intoxication or withdrawal: alcohol, stimulants, anabolic steroids, and benzodiazepine withdrawal can each produce aggression; IED is not diagnosed if outbursts occur only in the context of substance use.¹¹

Medical mimics to rule out

• Traumatic brain injury, particularly frontal or temporal injury, can produce a phenocopy of impulsive aggression and warrants neurologic history and exam.¹³
• Complex partial (focal-aware or focal-impaired-awareness) seizures with ictal or post-ictal aggression, rare but important; the stereotyped, automatism-laden quality and post-ictal confusion are distinguishing features.¹³
• Hyperthyroidism, hypoglycemia, hepatic encephalopathy, and Wilson disease can each present with irritability or aggression.¹³
• Dementia (frontotemporal dementia in particular) presents with disinhibited aggression in mid-to-late life and is not IED.¹³
• Delirium from any cause can cause aggressive outbursts; the fluctuating sensorium and inattention distinguish it.¹³

Diagnosis is clinical and rests on a detailed outburst history, collateral information, and exclusion of mimics, supplemented by validated rating scales rather than replaced by them.⁶

History elements

• Outburst phenomenology: number per week, triggers, duration, peak intensity, presence of property damage or physical injury, and post-outburst affect.⁶
• Age of onset, course, and prior treatment history including specific anger-directed interventions.^1,6
• Comprehensive screen for comorbid mood, anxiety, substance use, ADHD, personality, and trauma-related disorders.^1-2
• Lifetime history of self-directed violence and other-directed violence, including domestic violence, weapon use, and legal involvement.¹
• Developmental, traumatic, and family history, with particular attention to childhood maltreatment and parental psychopathology.^3,10
• Collateral history from a partner, parent, or other close contact whenever possible. Patients consistently under-report frequency and severity of outbursts.⁶

Physical examination

• Vital signs and a basic neurologic exam, including cranial nerves, motor and reflex symmetry, and a brief frontal-release screen, are appropriate in any first evaluation for new-onset aggression.¹³
• Look for signs of substance use, head injury, thyroid disease, and chronic medical illness.¹³

Validated rating scales

• Overt Aggression Scale-Modified (OAS-M): clinician-rated weekly aggression instrument used as the primary outcome in most IED treatment trials.¹⁴
• Buss-Perry Aggression Questionnaire (BPAQ): 29-item self-report covering physical aggression, verbal aggression, anger, and hostility.⁶
• Intermittent Explosive Disorder Screening Questionnaire (IED-SQ): a brief self-report designed to identify likely DSM-5 IED cases in clinical and research settings.¹⁵
• Life History of Aggression (LHA): retrospective measure of lifetime aggression, antisocial behavior, and self-directed aggression.⁶

Labs and imaging

• For typical presentations with adolescent onset and no neurologic red flags, an initial panel of TSH, CBC, comprehensive metabolic panel, and toxicology screen is reasonable; targeted workup is otherwise driven by history and exam.¹³
• Neuroimaging is not routine; reserve MRI or EEG for late-onset cases, focal neurologic findings, or atypical features such as automatisms, prolonged confusion, or true loss of consciousness.¹³
• Genetic and biomarker testing, including CSF 5-HIAA and inflammatory markers, remains a research tool and is not part of standard clinical workup.⁶

The evidence base for IED treatment is small relative to other DSM disorders: roughly a handful of randomized trials anchor the field, supplemented by open-label studies and expert consensus. No medication carries an FDA indication for IED, and all pharmacotherapy is off-label.^6,16

Pharmacotherapy

• Fluoxetine has the best randomized evidence: in a 12-week trial of 100 adults with IED, fluoxetine reduced Overt Aggression Scale-Modified aggression scores significantly more than placebo, with response in roughly 46% and full remission in 29%.¹⁶
• Other SSRIs are commonly used by extension, with citalopram, sertraline, and paroxetine supported mainly by open-label and personality-disorder aggression studies.⁶
• Mood stabilizers (divalproex, lithium, carbamazepine, oxcarbazepine) are widely used clinically for impulsive aggression, but trial evidence specific to DSM-5 IED is limited; a small 12-week RCT of fluoxetine and divalproex in 30 adults with IED did not detect aggression reduction by either drug in that sample.¹⁷
• Atypical antipsychotics, particularly risperidone and aripiprazole, have evidence for aggression reduction in autism, dementia, and personality disorders, and are sometimes used adjunctively in IED, but specific IED-trial evidence is lacking.[CITE NEEDED]
• Beta-blockers (propranolol) have historical use for aggression in brain-injured populations and remain a second- or third-line consideration when impulsive aggression is intermixed with hyperarousal.[CITE NEEDED]
• Benzodiazepines are not recommended for chronic IED management: paradoxical disinhibition and dependence outweigh any short-term anxiolysis.⁶

Psychotherapy

• Cognitive behavioral therapy targeting anger and aggression has the strongest psychotherapy evidence: in a 45-patient RCT, both individual and group 12-week CBT reduced aggression, anger, and depressed mood compared with waitlist, with large effect sizes maintained at three-month follow-up.¹⁸
• A preliminary 16-session group CBT trial in adults with IED reported significant pre- to post-treatment reductions in aggression and anger, supporting feasibility of group delivery.¹⁹
• Core CBT components for IED include relaxation training, cognitive restructuring of provocation appraisals, coping-skills rehearsal, and graded in-session exposure to anger cues.¹⁸
• Combined pharmacotherapy plus CBT is not well-studied in IED specifically, though clinical practice extrapolates from depression and anxiety literature in favor of combined treatment for more severe presentations.⁶

Neuromodulation

• No randomized trials support repetitive transcranial magnetic stimulation, transcranial direct current stimulation, or electroconvulsive therapy as targeted treatments for IED.[CITE NEEDED]
• Use of neuromodulation should be reserved for treatment-resistant comorbid mood disorder rather than as primary IED therapy.⁶

Adjunctive

• Treat comorbidities aggressively: untreated major depression, alcohol use disorder, or PTSD will undermine any IED-specific intervention, and adequate treatment of comorbidity often reduces outburst frequency on its own.^1-2,6
• Couples and family interventions help when domestic conflict is a major outburst trigger, particularly when violence has crossed into the legal system.[CITE NEEDED]
• Substance use treatment is essential when alcohol or stimulants precipitate or amplify outbursts; sobriety alone can substantially reduce aggression frequency.⁶
• Safety planning, lethal-means counseling, and routine inquiry into firearms access are part of care for every patient with IED given the elevated rates of both self- and other-directed violence.^1,6

The IED evidence base is small, dominated by one research group, and characterized by modest effect sizes; harms of treatment must be weighed against incomplete benefits and chronic course.^6,16,18

Treatment harms

• SSRIs are generally well tolerated but carry GI, sexual, and bleeding adverse effects, with discontinuation syndrome on abrupt stop and a boxed warning for emergent suicidality in patients under 25.¹⁶
• Mood stabilizers used off-label for impulsive aggression carry substantive toxicity: lithium's narrow therapeutic window and renal-thyroid effects, divalproex's hepatotoxicity and teratogenicity, and carbamazepine's hematologic and dermatologic risks.¹⁷
• Antipsychotics for aggression-related symptoms carry metabolic, extrapyramidal, and sedation burdens, with elevated mortality in elderly patients with dementia.[CITE NEEDED]
• Behavioral interventions can transiently worsen anger early in treatment as patients confront aggression-related material; framing this for the patient improves retention.¹⁸

Limitations of the evidence base

• Only two published placebo-controlled medication RCTs and two psychotherapy RCTs specific to IED exist, all with sample sizes below 110.^16-19
• Most trials enrolled adults aged 18-55 with limited racial and ethnic diversity, restricting generalizability.^16,18
• No head-to-head trials compare fluoxetine to CBT, or either to combination treatment.⁶
• Follow-up beyond three to six months is rare; long-term efficacy and the durability of treatment gains are not established.^16,18
• Trial outcomes rely heavily on the OAS-M and related Coccaro-group instruments, which may overestimate treatment-specific effects relative to functional outcomes.⁶

Although the same diagnostic and treatment principles apply, several populations warrant tailored consideration.⁶

Children and adolescents

• DSM-5-TR requires age six or developmental equivalent; before that, persistent aggression is more appropriately framed within a developmental, attachment, or neurodevelopmental formulation.¹¹
• In children under 12 with persistent irritable mood between outbursts, disruptive mood dysregulation disorder is the better fit and should be diagnosed instead of IED.¹¹
• Family-based psychosocial interventions and parent management training are the recommended first-line approaches in younger patients; pharmacotherapy is reserved for failure or severe presentations.⁶

Older adults

• New-onset aggression after age 40 is rarely IED and should prompt workup for neurologic, metabolic, or substance-related causes.¹³
• Behavioral and environmental interventions take priority over pharmacotherapy in cognitive impairment and dementia-related aggression.¹³

Perinatal patients

• Divalproex and carbamazepine are contraindicated in pregnancy for impulsive aggression given teratogenicity and the modest evidence base.¹⁷
• Fluoxetine and sertraline have the largest reproductive safety data among SSRIs; risk-benefit discussion should be documented when continuing or initiating treatment in pregnancy.[CITE NEEDED]

Comorbid substance use and trauma

• Alcohol and stimulant use markedly amplify outburst risk; integrated substance use treatment is essential rather than optional.^1,6
• In patients with prominent trauma histories and intrusive symptoms, trauma-focused psychotherapy may reduce both PTSD symptoms and irritability/aggression, though direct IED-outcome data are limited.[CITE NEEDED]

Cultural considerations

• Cross-national prevalence varies more than tenfold, and norms around verbal aggression, public display of anger, and disclosure of violence differ substantially across cultures; case finding should account for these norms.^3-4

IED is typically chronic but partially treatable, with most patients showing some attenuation of outburst frequency over time and a meaningful subset achieving substantial response to first-line treatment.^1,16,18

Natural history

• Without treatment, fewer than 30% of NCS-A adolescents with IED achieved remission of impulsive aggression in early adulthood.²
• Outburst frequency typically peaks in adolescence and early adulthood and declines from middle age onward.¹

Treatment response

• In the fluoxetine RCT, partial response (>50% OAS-M reduction) was achieved in roughly half of completers, with full remission in fewer than one-third.¹⁶
• CBT in the McCloskey pilot RCT achieved large within-group effect sizes for aggression and anger and outperformed wait-list at 12 weeks and at three-month follow-up.¹⁸

Mortality and morbidity

• Suicide attempt risk is elevated approximately three- to fivefold in IED relative to non-IED controls, independent of comorbid mood disorder.¹
• Interpersonal violence, motor vehicle aggression, and arrest history contribute to morbidity and to legal consequences that may complicate future treatment.^1,6
• Despite the high burden, only a minority receive anger-directed treatment, and most diagnosed cases are identified only when comorbid conditions bring the patient to care.¹

Acute IED outbursts in the clinic, ED, or inpatient setting are managed with the same principles used for any agitated patient: environmental de-escalation first, sedating medication next, restraint as last resort.¹³

Acute management

• Verbal de-escalation, environmental modification (reducing stimuli, providing space), and offer of oral PRN are the first interventions for acute agitation.¹³
• Oral lorazepam (1-2 mg) or oral olanzapine (5-10 mg) is reasonable for moderate agitation when oral route is feasible; intramuscular options include haloperidol, lorazepam, or olanzapine for severe agitation.¹³
• Physical restraint should be reserved for imminent danger and used for the shortest possible duration, with frequent reassessment.¹³

Hospitalization criteria

• Acute suicidality with means and intent, particularly after an outburst with high-lethality means available, warrants inpatient admission.^1,13
• Acute homicidality with identifiable target requires inpatient admission and triggers state-specific duty-to-warn or duty-to-protect obligations.¹³
• New-onset aggression with neurologic or systemic signs warrants medical admission for workup rather than psychiatric admission.¹³

IED has been a contested category since DSM-III and remains so under DSM-5-TR. The unresolved questions matter clinically because they shape how the diagnosis is made and treated.

Diagnostic validity

• Critics argue that IED captures a final common pathway of impulsive aggression that crosses diagnostic boundaries, rather than a discrete disorder; supporters point to distinct neurobiology, family history, and course as evidence for categorical status.⁶
• The DSM-5 broadening to include twice-weekly non-destructive outbursts expanded prevalence sharply and remains debated; some authors view it as appropriately inclusive, others as diagnostic inflation.^6,11

Comorbidity versus diagnostic redundancy

• High comorbidity with antisocial and borderline personality disorders, ADHD, and substance use disorders raises the question of whether IED is a distinct disorder or an aggression dimension that should be coded across diagnoses.⁶
• Cross-national WMH data identify externalizing-spectrum subtypes of IED that may not be well captured by a single diagnostic label.⁴

Evidence base and treatment access

• The pharmacologic evidence base rests on a small number of trials, none large, and remission rates with SSRI monotherapy remain below 50%.¹⁶
• No FDA-approved medication exists for IED; all pharmacotherapy is off-label, with the practical consequence that insurance coverage and patient access are inconsistent.[CITE NEEDED]
• Most patients with IED never receive aggression-specific treatment, in part because the diagnosis is not made, and in part because effective interventions are not widely disseminated.¹

Forensic and stigma considerations

• The use of IED as a partial mitigating factor in criminal proceedings is contested; the diagnosis does not negate criminal responsibility but may inform sentencing or treatment recommendations.[CITE NEEDED]
• Naming aggression as a psychiatric disorder risks both reducing stigma (by framing it as treatable) and increasing it (by labeling). Clinicians should weigh both, especially with adolescents and patients in legal contexts.⁶

• DSM-5-TR places intermittent explosive disorder under Disruptive, Impulse-Control, and Conduct Disorders.¹¹
• Minimum age for the diagnosis is six years or developmental equivalent.¹¹
• DSM-5-TR allows either twice-weekly verbal or non-destructive physical outbursts over three months, or three destructive outbursts over twelve months.¹¹
• Outbursts in IED are impulsive (not premeditated) and not committed for tangible gain.¹¹
• Lifetime prevalence in US adults was 7.3% (broad criteria) in NCS-R.¹
• Mean age of onset is 12-14 years across major epidemiologic surveys.^1-2
• Men are affected approximately twice as often as women in community samples.³
• IED in adolescence typically precedes onset of comorbid mood, anxiety, and substance use disorders.²
• Functional MRI shows amygdala hyperreactivity and reduced orbitofrontal activation to angry faces in IED.⁷
• Heritability estimates for impulsive aggressive traits in twin studies range from 28% to 47%.⁹
• Fluoxetine has the strongest randomized trial evidence among medications for IED but produces remission in fewer than half of patients.¹⁶
• Cognitive behavioral therapy targeting anger, in group or individual format, reduces aggression and anger in randomized trials.¹⁸
• IED should not be diagnosed if outbursts occur only during a manic, depressive, or psychotic episode, or only during substance intoxication or withdrawal.¹¹
• A first explosive episode in a patient over 40 with no prior history warrants medical and neurologic workup before assigning IED.¹³
• Patients with IED have elevated rates of suicide attempts and interpersonal violence, requiring direct assessment of both at every visit.^1,6

No external funding. No conflicts of interest declared. Peer-review status: pending.